BlossomHill Therapeutics (BLSM)
Develops oral small-molecule cancer therapies for EGFR, CLK and KRAS targets.
BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer
Data to be presented in a mini-oral session will describe anti-tumor activity of BH-30643 in patients with secondary EGFR resistance mutations such as EGFR C797S BH-30643 was recently granted Fast Track designation by the FDA for the treatment of C797S-positive resistance in EGFR-mutant NSCLC, a setting where no oral targeted therapies are approved SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced that updated data from the ongoing Phase 1/2 SOLARA trial describing anti-tumor activity of BH-30643 in patients with secondary epidermal growth factor receptor (EGFR) resistance mutations such as EGFR C797S will be shared as a mini-oral presentation on September 15, 2026 at the 2026 World Conference on Lung Cancer in Seoul, South Korea.
BlossomHill Therapeutics (NASDAQ:BLSM) Director Bihua Chen Purchases 312,500 Shares of Stock
BlossomHill Therapeutics, Inc. (NASDAQ: BLSM - Get Free Report) Director Bihua Chen acquired 312,500 shares of the business's stock in a transaction dated Monday, August 10th. The shares were bought at an average price of $16.00 per share, for a total transaction of $5,000,000.00. Following the acquisition, the director owned 3,614,034 shares of the company's stock,
BlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public Offering
SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. , (“BlossomHill Therapeutics”), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to develop innovative small molecule medicines for the treatment of cancer, today announced the pricing of its upsized initial public offering of 9,375,000 shares of common stock at a price to the public of $16.00 per share. The gross proceeds to BlossomHill Therapeutics from the offering, before deducting underwriting discounts and commissions and offering expenses payable by BlossomHill Therapeutics, are expected to be $150.0 million, excluding any exercise of the underwriters' option to purchase additional shares. In addition, BlossomHill Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,406,250 shares of common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being offered by BlossomHill Therapeutics.
BlossomHill Therapeutics Aims For $125 Million IPO On Cancer Treatment Pipeline Promise
BlossomHill Therapeutics is seeking a $125 million IPO to advance its oncology pipeline, focused on EGFR-mutant NSCLC. I see early clinical data for BH-30643 as promising, supporting a potential accelerated FDA pathway for this large, fast-growing market. IPO proceeds will fund Phase 2 trials, pipeline expansion, and provide runway into Q1 2028, supporting long-term value creation.
